Skip to main content
Premium Trial:

Request an Annual Quote

Isogen to Distribute Axela Platforms

NEW YORK (GenomeWeb News) – Isogen Life Science will distribute Axela's multiplex biomarker platforms in Benelux and Spain under an agreement announced by the firms today.

Isogen, based in De Meern, The Netherlands, will manage sales and support of Axela's flow through systems to clinical research markets in the designated countries. Platforms covered by the deal include Axela's Ziplex Research System for gene and protein microarray analysis, the dotLab mX System for real-time multiplex immunoassays, and the panelPlus technology for creating custom multiplex panels for biomarker analysis.

Financial and other terms of the alliance were not disclosed.

"The Ziplex and dotLab mX product range nicely complement our portfolio of distributed and internally developed products for life science research markets," Isogen Managing Director Hans Beijersbergen van Henegouwen said in a statement. "Working closely with the Axela team, we will be able to provide our customers with robust, time-saving solutions for their biomarker discovery and validation projects."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more